Quality, economics, and national guidelines for transcatheter aortic valve replacement

Peter M. Pollak, Michael J. Mack, David R. Holmes

Research output: Contribution to journalArticlepeer-review

13 Scopus citations


Transcatheter aortic valve replacement (TAVR) is a transformative technology for the treatment of aortic stenosis, requiring a multidisciplinary collaboration in the form of a "heart team" that includes interventional cardiologists and cardiac surgeons. As this new technology continues to disperse rapidly, its proper therapeutic role evolves and leads to important questions regarding who should perform the procedure, where it should be performed, and who should pay for it. Herein, we review the most recent guidelines governing the use of TAVR in the United States and Europe. We then summarize the available registry data, which, despite its limitations, presents the clearest picture of TAVR in clinical use. Finally, we discuss the costs and relative cost-effectiveness of TAVR. Taken together, these are the elements from which the larger questions surrounding TAVR must be answered.

Original languageEnglish (US)
Pages (from-to)610-618
Number of pages9
JournalProgress in Cardiovascular Diseases
Issue number6
StatePublished - May 2014


  • Aortic stenosis
  • Cost
  • Cost-effectiveness
  • National guidelines
  • Quality
  • Transcatheter aortic valve replacement

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'Quality, economics, and national guidelines for transcatheter aortic valve replacement'. Together they form a unique fingerprint.

Cite this